Weight loss drugs are more likely to be covered on government-funded insurance than on private plans
New data shows that government-funded health insurance plans in the United States provide the majority of coverage for ...
New Weight Loss Drug Boosts Energy and Reduces Appetite Without Side Effects
Researchers at the University of Copenhagen have identified a new drug target for weight loss that curbs appetite, boosts ...
Weight-loss drug Wegovy launched in China
Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.
First for Women on MSN4h
NK2R: A Side-Effect-Free Ozempic Alternative for Weight Loss
Ozempic, Wegovy and Mounjaro are often the most popular weight loss drugs. While these medications help people lose weight, ...
News Medical on MSN13h
Tirzepatide improves heart health and function in obese HFpEF patients
In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...
Medicaid fuels US coverage of Novo, Lilly weight-loss drugs
U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...
Medicaid dominates coverage of Novo, Lilly weight-loss drugs
State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...
Tirzepatide yields sustained weight reduction in obesity and prediabetes, finds study
For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes, according to a study ...